Double-blind controlled clinical trial of clofazimine in reactive phases of lepromatous leprosy.
A double-blind controlled trial in 24 lepromatous leprosy patients in reaction showed that clofazimine (Lamprene) controlled symptoms of erythema nodosum leprosum reaction in lepromatous leprosy better than prednisolone. Clofazimine also appeared to be significantly superior in preventing recurrence once the reaction had been controlled. There was a statistically significant rise in serum albumin among inpatients on clofazimine as compared with patients on prednisolone, but no difference in terms of neurological status, bacterial index, morphological index, and renal functions. Red/black hyperpigmentation was seen among practically all patients on clofazimine. No other side-effects or deleterious systemic effects were observed.
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004893:Erythema Nodosum / Q000188:drug therapy; D006801:Humans; D007918:Leprosy / Q000188:drug therapy*; D010619:Phenazines / Q000009:adverse effects / Q000627:therapeutic use*; D010859:Pigmentation Disorders / Q000139:chemically induced; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D012709:Serum Albumin
D000893:Anti-Inflammatory Agents; D010619:Phenazines; D012709:Serum Albumin; D011239:Prednisolone